SK Biopharmaceuticals Revenue and Competitors

Location

N/A

Total Funding

Telecom

Industry

Estimated Revenue & Valuation

  • SK Biopharmaceuticals's estimated annual revenue is currently $1.7B per year.(i)
  • SK Biopharmaceuticals's estimated revenue per employee is $455,000

Employee Data

  • SK Biopharmaceuticals has 3714 Employees.(i)
  • SK Biopharmaceuticals grew their employee count by -41% last year.

SK Biopharmaceuticals's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$42.9M132-7%N/AN/A
#2
$3.3M17-6%N/AN/A
#3
$6.1M27-21%N/AN/A
#4
$162.5M40016%N/AN/A
#5
$15.8M540%N/AN/A
#6
$42.6M1318%N/AN/A
#7
$17.8M61-14%N/AN/A
#8
$1.2M16-11%$1.3MN/A
#9
$0.3M90%$25MN/A
#10
$597.9M131423%N/AN/A
Add Company

What Is SK Biopharmaceuticals?

SK Biopharmaceuticals is a part of the global conglomerate SK Group, the second largest company in Korea. We’re responsible for the development of innovative next-generation drugs within SK Group. SK Biopharmaceuticals has been developing many new drug candidates in the area of CNS, led by the clinical development center(SK Life Science) located in United States and the research center in Pangyo Techno-valley, Gyeonggi-do. With the experience and expertise in the CNS area, SK Biopharmaceuticals will continue to thrive as a successful new drug development company and become a trusted partner through its global R&D network. By 2020, SK Biopharmaceuticals envisions to grow into a global Fully Integrated Pharmaceutical Company (FIPCO) with streamlined capabilities from research to marketing. For more information, visit our website at www.skbp.com.

keywords:N/A

N/A

Total Funding

3714

Number of Employees

$1.7B

Revenue (est)

-41%

Employee Growth %

N/A

Valuation

N/A

Accelerator

SK Biopharmaceuticals News

2022-04-13 - Ubix Therapeutics, SK Biopharmaceuticals enter into research ...

Ubix Therapeutics, SK Biopharmaceuticals to develop new compounds and medicines through Ubix's Degraducer® technology for cancer treatment.

2022-03-30 - SK life science Presents Long-term Data on Cognitive and ...

Cenobamate is an anti-seizure medication (ASM) discovered and developed by SK Biopharmaceuticals and SK life science. While the precise...

2022-03-22 - Axsome Therapeutics to Acquire Sunosi® from Jazz ...

Axsome will also assume the commitments of Jazz to SK Biopharmaceuticals (SK) and Aerial Biopharma (Aerial). SK is the originator of Sunosi...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$52160M37142%N/A
#2
$1149.1M3731-2%N/A
#3
$1327.1M37327%N/A
#4
$1423.9M37671%N/A
#5
$1319.2M37696%N/A